NEW YORK (GenomeWeb) – The Association of Molecular Pathology has published recommendations to help guide management of patients with chronic myeloid neoplasms.
The recommendations, published this week in the Journal of Molecular Diagnostics, call for including a minimum of 34 specific genes in targeted sequencing panels.
The AMP CMN working group “recognized a clear unmet need for evidence-based recommendations to assist in the development of the high-quality pan-myeloid gene panels that provide relevant diagnostic and prognostic information and enable monitoring of clonal architecture,” Rebecca McClure, an associate professor at the Northern Ontario School of Medicine and a co-lead author of the study, said in a statement.
Because there are multiple forms of CMNs, including myelodysplastic syndromes and myeloproliferative neoplasms, there is a lot of variability in the genes that are currently included on targeted next-generation sequencing panels used to diagnose or manageme patients, the authors wrote.
The AMP working group thus reviewed more than 600 published studies relating to DNA variants in all forms of adult CMNs that were not chronic myeloid leukemia, and including the syndromes clonal hematopoiesis of indeterminate origin and clonal cytopenia of undetermined significance, which involve having variants in myeloid genes without clinical features of a myeloid neoplasm.